Comparative effectiveness of first line pembrolizumab vs. chemotherapy in aNSCLC: A Norwegian Population-Based Cohort Study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
The KEYNOTE-042(1,2) trial showed a benefit of treating patients with non-oncogene addicted advanced NSCLC with PD-L1 tumour proportion score over 50% with Pembrolizumab as monotherapy over platinum doublet chemotherapy. To contextualize these results, we undertake a detailed emulation of the inclusion criteria in Keynote–042 using Norwegian health registry data, and discuss both the clinical context, as well as the general utility of such registry data for pharmacoepidemiologic research in oncology. Within the population of patients with PD-L1 tumour proportion score over 50%, an observational analogue of an intention to treat analysis showed similar results to those of the Keynote-042 study.
